EyePoint宣布Duravyu™治疗糖尿病黄斑水肿的两项全球三期临床试验首批患者完成给药

美股速递
Mar 02

EyePoint Pharmaceuticals宣布,其创新药物Duravyu™针对糖尿病黄斑水肿治疗的两项全球三期临床试验已成功完成首批患者给药。这一重要进展标志着该疗法向商业化迈出关键一步,为全球数百万糖尿病患者带来新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10